Key facts
- This page summarizes TPAV, LLC's Form 4 filing for Traws Pharma, Inc. (TRAW).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Apr 2025, 20:32.
TPAV, LLC - 02 Apr 2025 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TRAW
- Reported as of
- 02 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Apr 2025, 20:32:34 UTC
- Prior SEC filing
- 27 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ TPAV, LLC, By: Nikolay Savchuk, Manager
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
TPAV, LLC filed Form 4 for Traws Pharma, Inc. (TRAW) on 08 Apr 2025.
Change
- Previous filing in this sequence was filed on 27 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRAW
transaction
Common Stock
Other
- Transaction value
- Shares
- -605,531
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Apr 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRAW
transaction
Derivative
Series C Preferred Stock
Other
- Transaction value
- $0
- Shares
- -2,264
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 905,497
- Exercise price
- Footnotes
- F1, F2, F3, F4, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
TPAV, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
On April 2, 2025, the TPAV, LLC ("TPAV") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock ("Series C Preferred Stock") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16.
Footnote F2
On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock ("Series C Preferred Stock") reported in this Form 4 are presented on an after-reverse stock split basis.
Footnote F3
Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly.
Footnote F4
Each share of Series C Preferred Stock is convertible into 400 shares of the Issuer's common stock, subject to an issuance limitation that prohibits the holder from converting such shares of Series C Preferred Stock to the extent that, after giving effect to the issuance of shares of common stock after such conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) would beneficially own in excess of 19.99% of the shares of common stock of the Issuer then outstanding (the "Beneficial Ownership Limitation").
Footnote F5
Following stockholder approval of the conversion of the Series C Preferred Stock into shares of the Issuer's common stock, which was obtained on September 16, 2024, the shares of Series C Preferred are convertible into shares of common stock, subject to the Beneficial Ownership Limitation.
Footnote F6
The Series C Preferred Stock do not expire.